Bradykinin and the pathophysiology of angioedema

International Immunopharmacology

Volumn 3, Issue 3, 2003, Pages 311-317

  Cugno, Massimo ^a   Nussberger, Jürg ^b   Cicardi, Marco ^a   Agostoni, Angelo ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Angioedema; Angiotensin converting enzyme inhibitors; C1 inhibitor deficiency; Histamine; Plasma bradykinin; Urticaria

Indexed keywords

ANTIHISTAMINIC AGENT; BRADYKININ DERIVATIVE; BRADYKININ[1-9]; COMPLEMENT COMPONENT C1S INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HISTAMINE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ALLERGY; ANGIONEUROTIC EDEMA; CHILD; CLINICAL ARTICLE; COMPLEMENT DEFICIENCY; CONFERENCE PAPER; CONTROLLED STUDY; HEREDITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFLAMMATORY CELL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RADIOIMMUNOASSAY; REMISSION; STRESS; VENOUS BLOOD;

EID: 0037333909     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5769(02)00162-5     Document Type: Conference Paper

References (30)

1. Thrap M.D. Chronic urticaria. Pathophysiology and treatment approaches. J. Allergy Clin. Immunol. 98:1996;S325-S330.
2. Monroe E.W., Daly A.F., Shalhoub R.F. Appraisal of the validity of histamine-induced wheal and flare to predict the clinical efficacy of antihistamines. J. Allergy Clin. Immunol. 99:1997;S798-S806.
3. Agostoni A., Cicardi M. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine (Baltimore). 71:1992;206-215.
4. Cicardi M., Agostoni A. Hereditary angioedema. N. Engl. J. Med. 334:1996;1666-1667.
5. Donaldson V.H., Evans R.R. A biochemical abnormality in hereditary angioneurotic edema: absence of serum inhibitor of C1-esterase. Am. J. Med. 31:1963;36-44.
6. Caldwell J.R., Ruddy S., Schur P.H., Austen K.J. Acquired C1 inhibitor deficiency in lymphosarcoma. Clin. Immunol. Immunopathol. 1:1972;39-52.
7. Agostoni A., Cicardi M. Drug-induced angioedema without urticaria. Drug Safety. 24:2001;599-606.
8. Grossman E., Messerli F.H., Neutel J.M. Angiotensin II receptor blockers: equal or preferred substitutes for ACE inhibitors? Arch. Intern. Med. 160:1999;1905-1911.
9. Messerli F.H., Nussberger J. Vasopeptidase inhibition and angioedema. Lancet. 356:2000;608-609.
10. Bhoola K.D., Figueroa C.D., Worthy K. Bioregulation of kinins: kallikreins, kininogens and kininases. Pharmacol. Rev. 44:1992;1-80.
11. Cicardi M., Bergamaschini L., Zingale L.C., Gioffrè D., Agostoni A. Idiopathic nonhistaminergic angioedema. Am. J. Med. 106:1999;650-654.
12. Davis A.E. III C1-inhibitor and hereditary angioneurotic edema. Annu. Rev. Immunol. 6:1988;595-628.
13. Harpel P.C., Cooper N.R. Studies on human plasma C1-inactivator-enzyme interaction. Mechanisms of interaction with C1s, plasmin, and trypsin. J. Clin. Invest. 55:1975;593-604.
14. Landerman N.S., Webster M.E., Becker E.L., Ratcliffe H.E. Hereditary angioneurotic edema. Deficiency of inhibitor for serum globulin permeability factor and/or plasma kallikrein. J. Allergy. 33:1962;330-341.
15. Nilsson T., Back O. Elevated plasmin-alpha 2-antiplasmin complex levels in hereditary angioedema: evidence for the in vivo efficiency of the intrinsic fibrinolytic system. Thromb. Res., Suppl. 40:1985;817-821.
16. Cugno M., Hack C.E., de Boer A.J.M., Eerenberg A., Agostoni A., Cicardi M. Generation of plasmin during acute attacks of hereditary angioedema. J. Lab. Clin. Med. 121:1993;38-43.
17. Schapira M., Silver L.D., Scott C.F., Schmaier A.H., Prograis L.J. Jr.et al. Prekallikrein activation and high-molecular-weight kininogen consumption in hereditary angioedema. N. Engl. J. Med. 308(18):1983;1050-1053.
18. Curd J.G., Prograis L.J. Jr., Cochrane C.G. Detection of active kallikrein in induced blister fluids of hereditary angioedema patients. J. Exp. Med. 152:1980;742-747.
19. Fields T., Ghebrehiwet B., Kaplan A.P. Kinin formation in hereditary angioedema plasma: evidence against kinin derivative from C2 and in support of spontaneous formation of bradykinin. J. Allergy Clin. Immunol. 72:1983;54-60.
20. Shoemaker L.R., Shurman S.J., Donaldson V.H., Davis A.E. III Hereditary angioneurotic oedema: characterization of plasma kinin and vascular permeability-enhancing activities. Clin. Exp. Immunol. 95:1994;22-28.
21. Han E.D., MacFarlane R.C., Mulligan A.N., Scafidi J., Davis A.E. III Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J. Clin. Invest. 109:2002;1057-1063.
22. Cugno M., Cicardi M., Agostoni A. Activation of the contact system and fibrinolysis in autoimmune acquired angioedema: a rationale for prophylactic use of tranexamic acid. J. Allergy Clin. Immunol. 93:1994;870-876.
23. Kleniewsky J., Blankenship D.T., Cardin A.D., Donaldson V.H. Mechanism of enhanced kinin release from high molecular weight kininogen by plasma kallikrein after its exposure to plasmin. J. Lab. Clin. Med. 120:1992;129-139.
24. Sigler C., Annis K., Cooper K., Haber H., Van de Carr S. Examination of baseline levels of carboxypeptidase N and complement components as potential predictors of angioedema associated with the use of an angiotensin-converting enzyme inhibitor. Arch. Dermatol. 133:1997;972-975.
25. Adam A., Cugno M., Molinaro G., Perez M., Lepage Y., Agostoni A. Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors. Lancet. 359:2002;2088-2089.
26. Nussberger J., Cugno M., Amstutz C., Cicardi M., Pellacani A., Agostoni A. Plasma bradykinin in angioedema. Lancet. 351:1998;1693-1697.
27. Pellacani A., Brunner H.R., Nussberger J. Plasma kinins increase after angiotensin-converting enzyme inhibition in human subjects. Clin. Sci. 87:1994;567-574.
28. Nussberger J., Cugno M., Cicardi M. Bradykinin-mediated angioedema. N. Engl. J. Med. 347:2002;621-622.
29. Nussberger J., Cugno M., Cicardi M., Agostoni A. Local bradykinin generation in hereditary angioedema. J. Allergy Clin. Immunol. 104:1999;1321-1322.
30. Agostoni A., Cicardi M., Cugno M., Zingale L.C., Gioffrè D., Nussberger J. Angioedema due to angiotensin-converting enzyme inhibitors. Immunopharmacology. 44:1999;21-25.